Anda Apiñániz Emma, Zafon Carles, Ruiz Rey Irati, Perdomo Carolina, Pineda Javier, Alcalde Juan, García Goñi Marta, Galofré Juan C
Department of Endocrinology and Nutrition, Complejo Hospitalario de Navarra, Pamplona, Spain.
IdiSNA (Instituto de investigación en la Salud de Navarra), Pamplona, Spain.
Endocrine. 2020 Dec;70(3):538-543. doi: 10.1007/s12020-020-02371-9. Epub 2020 Jun 7.
The adequate extent of surgery for 1-4 cm low-risk papillary thyroid carcinoma (PTC) is unclear. Our objective was to analyze the applicability of the 2015 ATA Guidelines recommendation 35B (R35) for the management low-risk PTC.
This multicentre study included patients with low-risk PTC who had undergone total thyroidectomy (TT). Retrospectively we selected those who met the R35 criteria for the performance of a thyroid lobectomy (TL). The aim was to identify the proportion of low-risk PTC patients treated using TT who would have required reintervention had they had a TL in accordance with R35.
We identified 497 patients (400 female; 80.5%). Median tumor size (mm): 21.2 (11-40). A tumor size ≥2 cm was found in 252 (50.7%). Most of them, 320 (64.4%), were in Stage I (AJCC 7th Edition). Following R35, 286 (57.5%) would have needed TT. Thus, they would have required a second surgery had they undergone TL. The indications for reintervention would have included lymph node involvement (35%), extrathyroidal extension (22.9%), aggressive subtype (8%), or vascular invasion (22.5%). No presurgical clinical data predict TT.
The appropriate management of low-risk PTC is unclear. Adherence to ATA R35 could lead to a huge increase in reinterventions when a TL is performed, though the need for them would be questionable. In our sample, more than half of patients (57.5%) who may undergo a TL for a seemingly low-risk PTC would have required a second operation to satisfy international guidelines, until better preoperative diagnostic tools become available.
1-4厘米低风险乳头状甲状腺癌(PTC)的手术切除范围尚无定论。我们的目的是分析2015年美国甲状腺协会(ATA)指南推荐35B(R35)在低风险PTC管理中的适用性。
这项多中心研究纳入了接受全甲状腺切除术(TT)的低风险PTC患者。我们回顾性地选择了那些符合甲状腺叶切除术(TL)R35标准的患者。目的是确定按照R35接受TL治疗的低风险PTC患者中,若接受TT治疗则需要再次干预的比例。
我们确定了497例患者(400例女性;80.5%)。肿瘤大小中位数(毫米):21.2(11 - 40)。252例(50.7%)肿瘤大小≥2厘米。其中大多数,320例(64.4%)为I期(美国癌症联合委员会第7版)。按照R³⁵,286例(57.5%)需要进行TT。因此,若他们接受了TL,则需要二次手术。再次干预的指征包括淋巴结受累(35%)、甲状腺外侵犯(22.9%)、侵袭性亚型(8%)或血管侵犯(22.5%)。术前临床数据无法预测是否需要TT。
低风险PTC的适当管理尚不清楚。遵循ATA R35进行TL时,再次干预的情况可能会大幅增加,尽管其必要性存疑。在我们的样本中,对于看似低风险的PTC可能接受TL的患者中,超过一半(57.5%)需要二次手术才能符合国际指南,直到有更好的术前诊断工具可用。